PharmaVentures advises IntoCell on Development and License Option Agreement with ADC Therapeutics
PharmaVentures are advisors for this collaboration and the ongoing partnering efforts for IntoCell’s platform technologies and its lead programme, B7-H3 ADC.
London, UK, 05 January 2023
PharmaVentures is pleased to announce that it acted as exclusive advisor for IntoCell on its agreement with ADC Therapeutics.
Stephen Waterman, Managing Director at PharmaVentures, said “We are pleased to have assisted IntoCell with this agreement, in addition to multiple research collaborations and MTAs previously executed, and we look forward to seeing the results of combining IntoCell’s linker-payload with ADC’s antibodies.”
Tae Kyo Park, Founder and CEO of IntoCell, said “We are pleased to be collaborating with ADC Therapeutics, one of the leading companies in the ADC area. We hope to leverage ADC Therapeutics’ experience with the development and commercialisation of its own ADC ZYNLONTA®. We have been working closely with PharmaVentures for the last few years, during which time PharmaVentures has been supporting our partnering efforts for our OHPAS and PMT platform technologies and our B7-H3 ADC.”
Fintan Walton, Founder and CEO of PharmaVentures, said “We are delighted to be supporting our client IntoCell with partnering advice. IntoCell is a great example of the emerging highly innovative Korean biotech sector. This latest deal highlights PharmaVentures’ success in helping Korean and Western Biopharma companies in forming alliances.”